New antibody combo offers hope for tough childhood cancer
NCT ID NCT01757626
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs—an antibody called Hu3F8 and a growth factor called GM-CSF—in children with high-risk neuroblastoma that has come back or not responded to standard therapy. The goal is to find the safest dose and understand side effects. About 186 participants are enrolled at Memorial Sloan Kettering Cancer Center.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a shorter chemo combo tame High-Risk neuroblastoma?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can AI read tumor slides to outsmart childhood cancer?
- Can a radioated molecule shrink untreatable neuroblastoma?
- Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma